EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.
Smolen JS, Edwards CJ, Konzett V, Laskou F, Aletaha D, Caporali R, Dörner T, Hyrich KL, Mateus E, Pope JE, Primdahl J, de Souza S, Stamm T, Takeuchi T, van der Heijde D, Verschueren P, Winthrop KL, Alvaro-Gracia JM, Askling J, Bathon J, Buch MH, Burmester GR, Codreanu C, Conaghan PG, Cutolo M, Fautrel B, Fonseca J, Gossec L, Haavardsholm E, Hetland ML, Iagnocco A, Juge PA, Li Z, Moe RH, Nash P, Poór G, Rubbert-Roth A, Sobrin RDS, Schulze-Koops H, Shumnalieva R, Senolt L, Silva-Fernandez L, Strangfeld A, Taylor P, Turesson C, van Duuren E, de Wit M, Xavier R, Kerschbaumer A, Landewé RBM.
Smolen JS, et al. Among authors: codreanu c.
Ann Rheum Dis. 2026 Mar 12:S0003-4967(26)00075-0. doi: 10.1016/j.ard.2026.01.023. Online ahead of print.
Ann Rheum Dis. 2026.
PMID: 41826212
Free article.